Phase II, open, single group,multicentre study to evaluate the efficacy and safety of Somatuline Autogel® (120 mg) administered every 4 weeks by deep subcutaneous injection in the tumour´s growth stabilization of patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy at the moment of study´s inclusion, the efficacy of Somatuline A...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

8-55-58102-002 : Essai de phase 2 randomisé, en double aveugle, évaluant l’efficacité du tasquinimod comme traitement de maintenance après une première ligne de chimiothérapie à base de docétaxel sans progression, chez des patients ayant un cancer de la prostate métastatique et résistant à la castration. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité du tasquinimod comme traitement de maintenance après une chimiothérapie à base de docétaxel sans progression, chez des patients ayant un cancer de la...

• Pays France
• Organes Prostate
• Spécialités Chimiothérapie, Thérapies Ciblées

IPSEN 8-55-52060-004 : Essai de phase 2 évaluant l’efficacité et la tolérance de différentes doses de BIM 23A760 chez des patients ayant un syndrome carcinoïde. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carci...

• Pays France
• Organes Cancers rares
• Spécialités Chimiothérapie

A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH DYNAMIC EQUINUS FOOT DEFORMITY DUE TO CEREBRAL PALSY The primary study objective is to assess the long term safety of repeated treatments with Dysport used in the treatment of lower limb spasticity in children with dynamic equinus foot deformity due to ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase III, multicentre study assesssing the long term safety and and efficay of repeated treatments with Dysport in the treatment of leg spasticity in adult patients with hemiparesis The primary study objective is to assess the long term safety of Dysport in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated Treatment Cycles.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

DKP 3M SC : Essai de phase 3, évaluant l’efficacité et la tolérance du pamoate de triptoréline par voie sous-cutanée, chez des patients ayant un cancer de la prostate localement avancé ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance d’un agoniste de l’hormone LHRH, le pamoate de triptoréline administré par voie sous-cutanée pendant trois mois, chez des patients ay...

• Pays France
• Organes Prostate
• Spécialités Hormonothérapie

An International, Multicentre, Prospective, Single Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction with a Guided Self Rehabilitation Contract in Adult Subjects with Spastic Hemiparesis The primary objective is to assess the responder rate as defined by the improvement of composite active range of motion (AROM) in the primary targeted limb, either upper limb (UL) or lower limb (LL), ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour The main objective is to assess the effect of lanreotide Autogel 120 mg administered every 28 days compared to placebo, on progression-free survival in patients with well or moderately differentiated ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

PHASE II MULTI-CENTRIC, RANDOMISED, OPEN-LABEL, PARALLEL-GROUP STUDY TO ASSESS THE NON-INFERIORITY OF PAMORELIN® 11,25MG SC INJECTED VERSUS PAMORELIN® 11,25MG IM INJECTED IN PATIENTS SUFFERING FROM ADVANCED PROSTATE CANCER To assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via standard intra...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE IV, OPEN-LABEL, RANDOMISED, CROSS-OVER STUDY TO ASSESS PATIENT PREFERENCE AND HEALTH ECONOMY IN PATIENTS WITH NEUROENDOCRINE TUMOURS, TREATED WITH LANREOTIDE AUTOGEL GIVEN AS SELF ADMINISTRATION To assess the patient preference of two lanreotide Autogel administration practices; self/partner or healthcare professional administration.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune